Developments in the Therapeutic Applications of Bisphosphonates

Journal of Clinical Pharmacology

Volumn 39, Issue 7, 1999, Pages 651-660

  Brown, Darwin L ^a   Robbins, Richard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM;

ANIMAL; BONE DISEASE; HUMAN; METABOLISM; REVIEW;

ANIMALS; BONE DISEASES; CALCIUM; DIPHOSPHONATES; HUMANS;

EID: 0033162931     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008272     Document Type: Article

References (52)

1. Fleisch H, Francis M, Russell RG: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969:165:1262-1266.
2. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P, et al: Structure-activity relationships of various bisphophonates. Calcif Tiss Intl 1983:35:87-99.
3. Guise T, Mundy G: Cancer and bone. Endocr Rev 1998;19:18-54.
4. Heaney R, Saville P: Etidronate disodium in postmenopausal osteoporosis. Clin Pharm Ther 1976;20:593-603.
5. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT: Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984;1:821-824.
6. Khairi MRA, Altman RD, DeRosa GP, Zimmerman J, Schenk RK, Johnston CC: Sodium etidronate in the treatment of Paget's disease of bone: a study of long-term results. Ann Int Med 1977;87:656-673.
7. Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
8. Fleisch H: Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 3rd ed. Berne, Switzerland: Parthenon, 1997.
9. Rosen C, Kessenich C: Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 1996;51:537-551.
10. Devogelaer JP, Malghem J, Stasse P, de Deuxchainses N: Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. Bone 1997;20:259-261.
11. Reginster JYL: Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992;13:351-354.
12. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et al: Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocr Metab 1996;81:961-967.
13. Khan SA, Vasikaran S, McCloskey EV, Beneton MNC, Rogers S, Coulton L, et al: Alendronate in the treatment of Paget's disease of bone. Bone 1997;20:263-271.
14. Siris E, Chines A, Altman R, Brown J, Johnston C, Lang R, et al: Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Min Res 1998;13:1032-1038.
15. Watts NB, Harris ST, Genant H, Wasnich R, Miller P, Jackson R, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Eng J Med 1990;323:73-79.
16. Storm T, Thamsborg G, Steiniche T, Genant H, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Eng J Med 1990;322:1265-1271.
17. Miller PD, Watts NB, Licata A, Harris ST, Genant H, Wasnich R, et al: Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103:468-447.
18. Chestnut C, McClung M, Ensrud K, Bell N, Genant H, Harris S, et al: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-152.
19. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell N, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Eng J Med 1995;333:1437-1444.
20. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
21. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, et al: Effects of oral alendronate and intranasal calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-390.
22. Fleisch H: Bisphosphonates: mechanisms of action and clinical use in osteoporosis - an update. Harm Metab Res 1997;29:145-150.
23. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogalaer JP: Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tiss Intl 1997;61:266-271.
24. Struys A, Snelder A, Mulder H: Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid induced osteoporosis. Am J Med 1995;99:235-242.
25. Reid IR, Heap SW, Ibbertson HK, King AR: Two year follow up of bisphosphonate APD treatment in steroid osteoporosis. Lancet 1988;2:1144-1148.
26. Reid I: Glucocorticoid osteoporosis: mechanisms and management. Eur J Endocr 1997;137:209-217.
27. Reid IR, Ibbertson HK, King AR, Alexander CJ: Prevention of steroid induced osteoporosis with (3 amino-1-hydroxypropylidene)-1,1 bisphosphonate (APD). Lancet 1988;1:143-146.
28. Saag K, Emkey R, Schnitzer T, Brown J, Hawkins F, Goemaere S, et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Eng J Med 1998;339:292-299.
29. Reasner C, Stone M, Hosking D, Ballah A, Mundy GR: Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocr Metab 1993;77:1067-1071.
30. Kanis J, McCloskey E: Bone turnover and biochemical markers in malignancy. Cancer 1997;80(Suppl.):1538-1545.
31. Lipton A: Bisphosphonates and breast carcinoma. Cancer 1997;(Suppl.):1668-1673.
32. Body JJ, Dumon JC: Treatment of tumor-induced hypercalcemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Ann Onc 1994;5:359-363.
33. Body JJ: Clinical research update zoledronate. Cancer 1997;80(Suppl.):1699-1701.
34. Kanis JA, McCloskey E: Clodronate. Cancer 1997;80(Suppl.): 1691-1695.
35. Coleman RE, Purohit OP, Vinholes JJ, Zekri J: High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997;80(Suppl.):1686-1690.
36. Van Holten-Verzantvoort ATM: Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996;32A:450-454.
37. Berenson JR, Lichtenstein A, Porter L: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Eng J Med 1996;334:488-493.
38. Pelger RCM, Hamdy NAT, Zwinderman AH, Lycklama AB, Nijeholt A, Papapoulos SE: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998;20:403-406.
39. Scheid V, Buzdar AV, Smith TL, Hortobagyi GN: Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58:2589-2593.
40. Diel I, Solomayer EF, Costa S, Gollan C, Goerner R, Wallweiner D, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New Eng J Med 1998;339:357-363.
41. Hortobagyi GN, Thierault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Eng J Med 1996;335:1785-1791.
42. Kanis JA, Powles T, Paterson A: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-667.
43. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Harson J, Ashley S: Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Onc 1993;11:59-65.
44. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, et al: Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Min Res 1995;10:697-701.
45. Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P: Single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 1988;85:207-212.
46. Ryan PJ, Sherry M, Gibson T, Fogelman I: Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD). Br J Rheum 1991;31:97-101.
47. Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA: Duration of response with oral clodronate in Paget's disease of bone. Bone 1996;18:185-190.
48. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J: Continuous therapy with pamidronate, a potent bisphosphonate, in the treatment of postmenopausal osteoporosis. J Clin Endocr Metab 1994;79:1595-1599.
49. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, et al: Comparative study of pamidronate and etidronate sodium in the treatment of cancer related hypercalcemia. J Clin Oncol 1992;10:134-142.
50. Douglas DL, Duckworth T, Russel RGG, Kanis JA, Preston CJ, Preston EF, et al: Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcemia due to primary hyperparathyroidism or malignant disease. Lancet 1980;1:1043-1047.
51. Hamdy N, Gray R, McCloskey EV, Galloway J, Rattenbury JM, Brown CB, et al: Clodronate in the medical management of hyperparathyroidism. Bone 1987;8(Suppl. 1):S69-S77.
52. Green J: Zoledronate: the preclinical pharmacology. Br J Clin Pract 1996;87(Suppl.):16-18.